Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome

Author(s)

de Almeida, Luciana Yamamoto ^{[1, 2]} ; Pereira-Martins, Diego Antonio ^{[1, 2]} ; Gouvea Lima, Ana Silvia ^[1] ; Baggio, Marcia Sueli ^[3] ; de Araujo Koury, Luisa Correa ^[1] ; Lange, Ana Paula ^{[1, 2]} ; Bassi, Sarah Cristina ^[2] ; Scheucher, Priscila Santos ^[1] ; Rego, Eduardo Magalhaes ^{[1, 2, 4]}

Affiliation

^[1] Univ Sao Paulo, Dept Med Images Hematol & Clin Oncol, Hematol Div, Ribeirao Preto Med Sch, Ribeirao Preto - Brazil

^[2] Univ Sao Paulo, Ctr Cell Based Therapy, Ribeirao Preto Med Sch, Ribeirao Preto - Brazil

^[3] Univ Sao Paulo, Hosp Clin, Hemostasis Lab, Fac Med Ribeirao Preto, Ribeirao Preto - Brazil

^[4] Univ Sao Paulo, Fac Med, LIM31, Hematol Div, Hemoctr, Av Dr Eneas Carvalho Aguiar 155, 1st Floor, BR-05403000 Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: BMC CANCER; v. 20, n. 1 AUG 28 2020.
• Web of Science Citations: 0

Abstract

Background Differentiation syndrome (DS) is the main life-threatening adverse event that occurs in acute promyelocytic leukemia (APL) patients treated with all-trans retinoic acid (ATRA). Cytokine imbalances have been reported to play role during the developing of acute promyelocytic leukemia differentiation syndrome (APL-DS). However, the relationship between the plasma cytokine levels and their prognostic value for the prediction of DS developing in patients with APL during the treatment with ATRA and anthracyclines has not been previously reported. Methods In this study, we followed an APL cohort (n = 17) over 7 days of ATRA therapy in DS (n = 6) and non-DS groups (n = 11). Interleukin (IL)-1 beta, IL-6, IL-8, IL-10, IL-12p70 and TNF-alpha were measured in the peripheral blood plasma from 17 patients with APL and 11 healthy adult controls by using the cytometric bead array method. Results In non-DS patients, IL-8 plasma levels were significantly reduced in the seventh day of ATRA treatment (34.16; 6.99 to 147.11 pg mL(- 1)in D0 vs. 10.9; 0 to 26.81 pg mL(- 1)in D7;p = 0.02) whereas their levels did not discriminate between DS and non-DS development during the entire induction period (allp > 0.05 in D0, D3, and D7). No significant differences were found in IL-6 levels between groups (p > 0.05 in D0-D7). Other cytokines tested were all undetectable in patients with APL or healthy controls. Conclusions We demonstrated that the modulation of IL-8 following ATRA treatment may occur regardless of the development of DS and, therefore, does not appear to be a predictive biomarker to monitor the APL-DS. (AU)

• FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
• Grantee: Dimas Tadeu Covas
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
• FAPESP's process: 16/02713-2 - Effects of erlotinib and gefitinib therapy in combination with all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: in vitro, ex vivo and murine experimental model studies.
• Grantee: Luciana Yamamoto de Almeida
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 17/23117-1 - Evaluation of TP53/TP73 pathway in engraftment of acute promyelocytic leukemia cells in xenotransplantation model
• Grantee: Diego Antonio Pereira Martins
• Support Opportunities: Scholarships in Brazil - Doctorate